These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


986 related items for PubMed ID: 15287092

  • 1. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
    Shankar S, Singh TR, Srivastava RK.
    Prostate; 2004 Sep 15; 61(1):35-49. PubMed ID: 15287092
    [Abstract] [Full Text] [Related]

  • 2. The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice.
    Shankar S, Singh TR, Chen X, Thakkar H, Firnin J, Srivastava RK.
    Int J Oncol; 2004 May 15; 24(5):1133-40. PubMed ID: 15067334
    [Abstract] [Full Text] [Related]

  • 3. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR, Shankar S, Chen X, Asim M, Srivastava RK.
    Cancer Res; 2003 Sep 01; 63(17):5390-400. PubMed ID: 14500373
    [Abstract] [Full Text] [Related]

  • 4. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo.
    Shankar S, Chen X, Srivastava RK.
    Prostate; 2005 Feb 01; 62(2):165-86. PubMed ID: 15389801
    [Abstract] [Full Text] [Related]

  • 5. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN.
    Cancer Res; 2001 Jan 15; 61(2):759-63. PubMed ID: 11212279
    [Abstract] [Full Text] [Related]

  • 6. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP, Zisman A, Bonavida B.
    Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140
    [Abstract] [Full Text] [Related]

  • 7. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
    Zhang L, Fang B.
    Cancer Gene Ther; 2005 Mar 01; 12(3):228-37. PubMed ID: 15550937
    [Abstract] [Full Text] [Related]

  • 8. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
    Kandasamy K, Srinivasula SM, Alnemri ES, Thompson CB, Korsmeyer SJ, Bryant JL, Srivastava RK.
    Cancer Res; 2003 Apr 01; 63(7):1712-21. PubMed ID: 12670926
    [Abstract] [Full Text] [Related]

  • 9. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
    Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T.
    Cancer Res; 2005 Jul 15; 65(14):6364-70. PubMed ID: 16024639
    [Abstract] [Full Text] [Related]

  • 10. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells.
    Munshi A, McDonnell TJ, Meyn RE.
    Cancer Chemother Pharmacol; 2002 Jul 15; 50(1):46-52. PubMed ID: 12111111
    [Abstract] [Full Text] [Related]

  • 11. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
    Kang J, Bu J, Hao Y, Chen F.
    Prostate Cancer Prostatic Dis; 2005 Jul 15; 8(3):274-9. PubMed ID: 15897917
    [Abstract] [Full Text] [Related]

  • 12. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K, Douglas L, Delaney A, Houghton JA.
    Clin Cancer Res; 2004 Oct 01; 10(19):6650-60. PubMed ID: 15475455
    [Abstract] [Full Text] [Related]

  • 13. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
    Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M, Mizuguchi J.
    J Orthop Res; 2003 Sep 01; 21(5):949-57. PubMed ID: 12919886
    [Abstract] [Full Text] [Related]

  • 14. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

  • 15. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
    Tong X, Li H.
    Cancer Lett; 2004 Jul 08; 210(1):63-71. PubMed ID: 15172122
    [Abstract] [Full Text] [Related]

  • 16. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.
    Sun SY, Yue P, Hong WK, Lotan R.
    Cancer Res; 2000 Dec 15; 60(24):7149-55. PubMed ID: 11156424
    [Abstract] [Full Text] [Related]

  • 17. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
    Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK.
    Int J Mol Med; 2005 Dec 15; 16(6):1125-38. PubMed ID: 16273296
    [Abstract] [Full Text] [Related]

  • 18. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.
    Munshi A, Pappas G, Honda T, McDonnell TJ, Younes A, Li Y, Meyn RE.
    Oncogene; 2001 Jun 28; 20(29):3757-65. PubMed ID: 11439339
    [Abstract] [Full Text] [Related]

  • 19. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells.
    Sun SY, Yue P, Lotan R.
    Oncogene; 2000 Sep 14; 19(39):4513-22. PubMed ID: 11002424
    [Abstract] [Full Text] [Related]

  • 20. Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.
    Perego P, Ciusani E, Gatti L, Carenini N, Corna E, Zunino F.
    Biochem Pharmacol; 2006 Mar 14; 71(6):791-8. PubMed ID: 16438941
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 50.